MTOR and neoplasm: PD-L1 blockade impacts on tumor glycolytic pathway by inhibiting the PI3K/mTOR signaling and decreasing the expression of GLUT1, with a subsequently increased availability of glucose in the TME, favoring the metabolism of activated T cells and restoring IFNγ production [73].